RG

Regen BioPharma IncOOTC RGBP Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.001

Micro

Exchange

OOTC - OTC

RGBP Stock Analysis

RG

Uncovered

Regen BioPharma Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-70/100

Low score

Market cap $B

0.001

Dividend yield

Shares outstanding

5 048.43 B

Regen Biopharma, Inc. is a biotechnology company, which focuses on the immunology and immunotherapy space. The company is headquartered in La Mesa, California and currently employs 1 full-time employees. The company went IPO on 2014-09-03. The firm is engaged on the immunology and immunotherapy space. The firm is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. The company is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6.

View Section: Eyestock Rating